Psy Therapeutics, Inc.
- Sep 12, 2025 · D/A · $6,762,848 sold of $20,400,000 · 23 investors · min. No minimum reported · role: Director EDGAR ↗
- Aug 9, 2024 · D/A · $5,847,848 sold of $20,400,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
- Aug 10, 2023 · D/A · $3,972,115 sold of $20,400,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
- Dec 28, 2021 · D · $2,772,615 sold of $20,400,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
- Oct 2, 2019 · D · $3,967,692 sold of $4,297,692 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
Raised $6.76M from 23 investors (33% of the $20.4M target) as of the latest filing. Daniel is listed as director on 5 filings for this deal.
Sources
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.